To assess the strength of clinical study findings, regulatory authorities often request tipping point analyses to examine how extreme an assumption about imputed data would need to apply for conclusions to change. However what is a tipping point analysis, and how is one performed? What are the different approaches for continuous, binary and time to event data?
Kevin Ding (AstraZeneca) and Juan Abellan (GlaxoSmithKline) will present some practical examples.
Who is this event intended for? Statisticians working on regulatory submissions
What is the benefit of attending? To learn more about the 'how' and 'why' of tipping point analysis, using relevant examples from previous studies